ABPI response to NHS Commercial Framework

23 February 2021 Posted in News by Press Office

The NHS Commercial Framework for New Medicines has been published.

Today’s publication of the NHS commercial framework for new medicines provides welcome clarity on how companies can partner with the NHS and NICE to get new medicines to the patients who need them. Richard Torbett

The 2019 Voluntary Scheme for Branded Medicines Pricing and Access committed NHS England to publish a commercial framework, setting out more operational detail on the commercial arrangements with the pharmaceutical industry.

In response, Richard Torbett, Chief Executive of the ABPI, said:

"Today’s publication of the NHS commercial framework for new medicines provides welcome clarity on how companies can partner with the NHS and NICE to get new medicines to the patients who need them.

"As more new medicines are discovered, we need a system that can provide the right commercial flexibilities and that supports faster uptake and adoption of new treatments.

"The Framework provides important recognition of this, and the ABPI will work closely with NHS England as the Framework is reviewed and developed over time."

 

TAGS
  • NHS Commercial Framework for New Medicines

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​